Search

Displaying results 2651 - 2660 of 10000 in total
  1. Drug

    Prizloncabtagene autoleucel

    go.drugbank.com/drugs/DB18623
    Investigational

    C-CAR039 is an autologous Chimeric Antigen Receptors (CAR) T-cell therapy expressing CD19/CD20 bi-specific CAR.

    Synonyms: autologous T lymphocytes obtained from peripheral blood lymphocytes by leukapheresis, transduced with a self-inactivating, non-replicating lentiviral vector, encoding a bispecific chimeric antigen receptor, an autologous Chimeric Antigen Receptors (CAR) T-cell therapy expressing CD19/CD20 bi-specific CAR
  2. Drug

    VOR33

    go.drugbank.com/drugs/DB18624
    Investigational

    VOR33 is an allogeneic CRISPR/Cas9 genome-edited hematopoietic stem and progenitor cell (HSPC) therapy product lacking the CD33 protein.

  3. Drug

    CTX120

    go.drugbank.com/drugs/DB18625
    Investigational

    CTX120 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting B-cell maturation antigen.

    Synonyms: allogeneic CRISPR/Cas9-mediated genetically modified CAR T cells targeting B-cell maturation antigen
  4. Drug

    CTX110

    go.drugbank.com/drugs/DB18626
    Investigational

    CTX110 is an allogeneic CRISPR/Cas9-mediated genetically modified CAR T cell therapy targeting CD19 antigen.

    Synonyms: allogeneic CRISPR/Cas9-mediated genetically modified CAR T cells targeting CD19 antigen
  5. Drug

    AB-201

    go.drugbank.com/drugs/DB18629
    Investigational

    AB-201 is a CAR-NK cell therapy targeted against HER2.[L48340] It is under investigation for the treatment of HER2-positive cancers, including breast and gastric carcinomas.

    Synonyms: Ex vivo expanded allogeneic cord blood-derived NK cells that have been genetically modified to express a HER2-directed CAR and secrete IL-15
  6. Drug

    AVR-RD-05

    go.drugbank.com/drugs/DB18631
    Experimental

    AVR-RD-05 is a gene therapy comprising genetically modified autologous stem cells transduced _ex vivo_ with a lentiviral vector encoding the human iduronate-2-sulfatase (IDS) enzyme. … It is under investigation for the treatment of Hunter Syndrome (Mucopolysaccharidosis Type II, MPSII).

    Synonyms: Ex vivo, lentiviral vector (LV)-mediated, genetically modified autologous cell therapy intended for the stable provision of functional human iduronate-2-sulfatase (IDS) enzyme to subjects with Hunter syndrome
  7. Drug

    Zedenoleucel

    go.drugbank.com/drugs/DB18639
    Investigational

    MT-401 is an allogeneic multi-tumor-associated antigen-specific T-cell therapy.

  8. Drug

    ALLO-715

    go.drugbank.com/drugs/DB18640
    Investigational

    ALLO-715 is an allogeneic chimeric antigen receptor T Cell therapy targeting B cell maturation antigen (BCMA).

    Synonyms: Allogenic Chimeric Antigen Receptor T Cells Targeting B Cell Maturation Antigen (BCMA)
  9. Drug

    OTL-102

    go.drugbank.com/drugs/DB18642
    Experimental

    It is being investigated for the treatment of X-linked chronic granulomatous disease. … OTL-102 consists of autologous CD34+ enriched cells that contain hematopoietic stem and progenitor cells transduced ex vivo using a lentiviral vector encoding the human gp91phox gene.

    Synonyms: Autologous CD34+ enriched cell population that contains hematopoietic stem and progenitor cells transduced ex vivo using a lentiviral vector encoding the human gp91phox gene
  10. Drug

    OTL-203

    go.drugbank.com/drugs/DB18643
    Investigational

    OTL-203 is an autologous CD34+ enriched cell therapy that contains hematopoietic stem and progenitor cells transduced ex-vivo using a lentiviral vector encoding alpha-L-iduronidase gene.

    Synonyms: Autologous CD34+ enriched cell population that contains hematopoietic stem and progenitor cells transduced ex-vivo using a lentiviral vector encoding alpha-L-iduronidase gene